COPD

How to read this summary

• Canadian sources come first, international/US sources second. Each point has a source tag like ^[S1] or ^[U1]. The full list of tags is at the end.
• "WARNING" marks a conflict or an old document. "Unconfirmed" means it could not be verified in the sources used. Never trust an unconfirmed item without checking.
• PEBC follows Canada. When Canada and another guideline differ, the Canadian answer is the exam answer.
• IMPORTANT (newest guideline): the main Canadian guideline is the Canadian Thoracic Society (CTS) 2023 Guideline on Pharmacotherapy in Patients with Stable COPD ^[S1] (Can J Respir Crit Care Sleep Med 2023, accepted June 2023). It replaces the 2019 CTS update. CTS says it is a living guideline reviewed every year; no newer CTS COPD guideline was found in the library in October 2026.
• IMPORTANT (gap): ^[S1] says clearly that it does NOT cover smoking cessation, vaccines, self-management, pulmonary rehabilitation, long-term oxygen, noninvasive ventilation, surgery, palliative care or the treatment of acute exacerbations ^{[S1 p2]}. For those topics this summary uses the Canadian Task Force (smoking), the Canadian Immunization Guide (vaccines), Choosing Wisely Canada, the older ACCP/CTS 2015 guideline ^[S17] and the international GOLD 2026 report ^[U1]. GOLD is an international guideline (not American); it is a labelled extra and Canada wins when they differ.
• WARNING: several Health Canada labels in the library are older than 2023 (Spiriva Respimat 2019, Spiriva HandiHaler 2022). Newer versions may exist; they were not found.
• Health Canada drug labels (product monographs) can differ from the guideline. Those points, and the Canada vs GOLD differences, are collected in section 18 "Label vs guideline, and Canada vs international" and are NOT used in the MCQs.
• Page numbers: S1 uses the printed journal page. GOLD (U1) uses the printed report page. Drug labels use the section.
• Doses and numbers are for exam study, not for real patients.
• Abbreviations used: COPD = Chronic Obstructive Pulmonary Disease; FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; LLN = Lower Limit of Normal; mMRC = modified Medical Research Council (breathlessness scale); CAT = COPD Assessment Test; AECOPD = Acute Exacerbation of COPD; SABA = Short-Acting Beta2-Agonist; SAMA = Short-Acting Muscarinic Antagonist; LABA = Long-Acting Beta2-Agonist; LAMA = Long-Acting Muscarinic Antagonist; LABD = Long-Acting BronchoDilator; ICS = Inhaled CorticoSteroid; SITT = Single-Inhaler Triple Therapy; PDE4 = PhosphoDiEsterase 4; NAC = N-AcetylCysteine; pMDI = pressurized Metered-Dose Inhaler; DPI = Dry Powder Inhaler; VHC = Valved Holding Chamber (a spacer with a valve); LTOT = Long-Term Oxygen Therapy; NIV = Non-Invasive Ventilation; A1AT = Alpha-1 AntiTrypsin; QT = the heart-rhythm interval on an ECG.

1. What is COPD, and how is it diagnosed? (the pipes that stay narrow)

• COPD is a long-term lung disease where airflow out of the lungs is limited and stays limited. People get breathless, cough and bring up sputum. In Canada it is very common, and exacerbations are the main driver of health-care costs ^{[S1 p2]}.
• Daily-life picture: think of breathing out through a straw that has been squeezed. Even with effort, air leaves slowly. A bronchodilator (like a reliever puffer) can open the straw a little, but not back to normal.
• Spirometry is essential. A post-bronchodilator FEV1/FVC ratio below 0.70 confirms the diagnosis ^{[S1 p3]}. Some use the lower limit of normal (LLN, below the 5th percentile) instead; CTS says the fixed 0.70 ratio is more appropriate for finding people at risk of clinically significant COPD, but it may over- or under-estimate obstruction at the extremes of age ^{[S1 p3]}.
• How bad the airflow limit is = how far the post-bronchodilator FEV1 is reduced (percent of predicted). But spirometry alone only partly shows how sick a person is, so symptoms and exacerbation risk must also be assessed ^{[S1 p1, p3, Figure 3]}.
• Many people with COPD are undiagnosed and have symptoms, poor health and a higher risk of exacerbations, pneumonia and death. At the same time, spirometry is under-used, so smokers with symptoms may get inhalers they do not need ^{[S1 p3]}.
• Choosing Wisely Canada (Canadian Thoracic Society) item 1: do not start long-term maintenance inhalers in stable patients with suspected COPD unless post-bronchodilator airflow obstruction has been confirmed by spirometry. Consider COPD in anyone with breathlessness, chronic cough or sputum and a history of exposure (for example smoke); but not everyone with these symptoms has COPD ^{[S2 item 1]}.
• CTS did not recommend long-acting bronchodilators for symptomatic current or former smokers whose spirometry is normal (they do not meet COPD criteria): inhaled long-acting bronchodilators do not reduce symptoms in people not proven to have COPD ^{[S1 p14]}.
• International extra (GOLD 2026): the severity of obstruction is graded on the post-bronchodilator FEV1; the five key parts of the first assessment are airflow-limit severity, symptoms, past moderate and severe exacerbations, blood eosinophil count and other diseases ^{[U1 p37]}. GOLD says all people with COPD should be tested for alpha-1 antitrypsin deficiency (see section 13) ^{[U1 p48]}.

Must remember for the exam: COPD is confirmed only by post-bronchodilator spirometry (FEV1/FVC below 0.70). Do not start maintenance inhalers for "suspected COPD" without it.

Blueprint area: Clinical Care.

2. Symptoms, exacerbation risk and what "severity" means

2.1 The two scales and the cut-offs CTS uses (CTS 2023 ^{[S1 Table 1, p7]})

• mMRC is a breathlessness scale with 5 levels (0 to 4) ^{[U1 p23, p37]}. CTS: mMRC 1 = low symptom burden; mMRC 2 or more = moderate to high ^{[S1 p7]}.
• CAT (COPD Assessment Test) is an 8-item health-status questionnaire scored 0 to 40 ^{[U1 p39]}. CTS: CAT below 10 = low impact; CAT 10 or more = moderate to high ^{[S1 p7]}.
• FEV1 80% predicted is the CTS split: 80% or more = only mildly impaired; below 80% = impaired lung function ^{[S1 p7]}.

2.2 Exacerbation words and risk (CTS 2023 ^{[S1 p9, p11]})

• A COPD exacerbation is a flare-up with a change in at least one major symptom: more breathlessness, more sputum purulence (pus-coloured sputum) or more sputum volume ^{[S1 p11]}.
• MODERATE exacerbation = a flare-up treated with an antibiotic and/or oral corticosteroid (prednisone), without a hospital admission or emergency department (ED) visit ^{[S1 p9 footnote, p11]}.
• SEVERE exacerbation = a flare-up that needs hospital admission or an ED visit ^{[S1 p9, p11]}.
• LOW risk of exacerbations = 1 or fewer moderate exacerbations in the past year and no hospital or ED visit ^{[S1 p8 footnote, p9]}.
• HIGH risk of exacerbations = 2 or more moderate exacerbations OR 1 or more severe exacerbation in the past year ^{[S1 p9 footnote, p13]}.
• The best way to find people likely to flare again is their exacerbation history ^{[S1 p11]}. Severe exacerbations carry a poor outlook: more deaths, worse health, more flare-ups. After discharge, mortality can be as high as 6.1% within 90 days ^{[S1 p11, p13]}.
• Daily-life example: Mr. Alvi had two courses of prednisone and antibiotics last winter, so he counts as HIGH risk even though he was never in hospital. Mrs. Roy had one hospital stay, so she is also HIGH risk.
• Flare-ups also raise the risk of heart attack and stroke in the first days to a year afterwards ^{[S1 p13]}.
• Blood eosinophil count (a white blood cell type) is not part of the CTS recommendations, but CTS experts agree people with eosinophils of 300 cells/microlitre or more benefit more from ICS and are more likely to flare if ICS is withdrawn ^{[S1 p12, p15]}.

Must remember for the exam: low risk = 1 or fewer moderate flare-up and none in hospital; high risk = 2 or more moderate OR 1 or more severe. Symptom cut-offs: mMRC 2 or more, CAT 10 or more, FEV1 below 80% predicted.

Blueprint area: Clinical Care. Likely exam angle: classifying a patient as low or high risk.

3. Stop smoking and other non-medicine care

• Smoking cessation is the first step in COPD care. The Health Canada labels for Spiriva HandiHaler, Anoro, Ultibro, Trelegy and Breztri all say that counselling on smoking cessation should be the first step in treating patients with COPD who smoke, and that stopping smoking gives large symptom benefits and a survival advantage ^{[S10 4.1; S12 4.1; S13 4.1; S14 4.1; S15 4.1]}.
• Canadian Task Force on Preventive Health Care (2025), adults who smoke tobacco cigarettes ^[S9]:
• Ask about smoking status; encourage everyone who smokes to stop, and offer one or more recommended interventions (strong recommendation, high certainty).
• Use shared decision-making and a menu of options. There is no single best choice; patients may need several quit attempts ^[S9].
• Recommended options: advice from a health-care provider, individual or group counselling, text-message programs, self-help materials, and pharmacotherapy (bupropion, cytisine, nicotine replacement therapy (NRT), varenicline). Combining medicine and behavioural support is also recommended ^[S9].
• Suggested AGAINST (strong recommendation): acupuncture, hypnotherapy, laser therapy, St. John's wort, SAMe and similar. Suggested against e-cigarettes for quitting except in special circumstances (conditional): people who failed other options or insist may discuss them, knowing the long-term safety is unknown and nicotine addiction continues ^[S9].
• Exact dosing of the quit-smoking drugs was not in the file and is not given here (unconfirmed).
• Vaccines are part of non-drug care (see section 11).
• Self-management education: inhaler technique and re-checks, adherence, breathing and cough techniques, early recognition of a flare-up, a written action plan (when appropriate), physical activity, diet and not smoking ^{[S1 Figure 1, p3]}.
• Pulmonary rehabilitation: CTS 2023 says the best way to relieve breathlessness and improve health status is to combine the best drugs with pulmonary rehabilitation ^{[S1 p7]}. CTS/ACCP 2015: for moderate to very severe COPD with a flare-up in the last 4 weeks (for example after hospital), pulmonary rehabilitation is recommended to prevent further flare-ups; if the flare-up was longer ago it was not suggested for that purpose ^{[S17 rec 4, 5]}. GOLD: programs of 6 to 8 weeks bring most of the benefit; supervised exercise at least twice a week; people with high symptoms or flare-ups should be encouraged to join ^{[U1 p74-75]}. Starting early after discharge (within 4 weeks) improves quality of life and exercise capacity ^{[U1 p109]}.
• Exercise improves, but a gain in exercise ability does not always lead to more daily activity unless a behaviour (coaching) program is added ^{[S1 p7, p11]}.
• Written action plan with education and case management is suggested to cut hospital visits; education plus an action plan without case management did not ^{[S17 rec 9, 10]}.
• Choosing Wisely Canada item 7: do not delay talks about wishes and goals of care in people with serious or progressive lung disease such as COPD ^{[S2 item 7]}.
• Choosing Wisely Canada item 2: do not do CT lung-cancer screening in low-risk people. The Canadian Task Force recommendation named there is screening adults aged 55 to 74 with a 30 pack-year smoking history who smoke or quit less than 15 years ago, in an organized program ^{[S2 item 2]}. The Task Force document itself (CMAJ 2016) is not in the library, and no newer final Task Force update was found in a web check on 2026-10-24 (an update is in progress), so nothing different is shown.

Must remember for the exam: smoking cessation is the first step; use shared decision-making with a menu of options (counselling plus bupropion, NRT, varenicline or cytisine); pulmonary rehabilitation (6 to 8 weeks) improves symptoms; vaccines yearly/as scheduled.

Blueprint area: Clinical Care; Communication and Collaboration.

4. The medicine classes (what each does)

• Daily-life picture: the SABA is a fire extinguisher (quick relief when you are short of breath). LAMA and LABA are the thermostat that keeps the pipes more open all day. The ICS is the repair crew that quiets the inflammation, but it can cause side effects, so it is added only when the person benefits.
• SABA/SAMA are "rescue": SABA as needed should go with all recommended therapies across all COPD severities ^{[S1 Figure 3 note p14; p13]}.
• Salbutamol (Ventolin HFA) label: indicated for relief and prevention of bronchospasm in asthma, chronic bronchitis and other chronic bronchopulmonary disorders; adults and adolescents over 12: 1 to 2 puffs (100 to 200 mcg) as needed; for prevention 1 to 2 puffs every 4 to 6 hours to a maximum of four times a day; maximum 8 puffs (800 mcg) a day. If a usual dose gives less relief than usual, or the effect lasts less than three hours, get prompt medical advice ^{[S16 sections 1, 4.1, 4.2]}.
• Side effects of beta2-agonists: fast heartbeat, tremor, low potassium (more with high or nebulised doses, and added by diuretics, steroids and xanthines), paradoxical bronchospasm (stop and get another treatment) ^{[S16 sections 7, 9; U1 p144]}.
• Side effects of muscarinic blockers: dry mouth is the main one; caution in narrow-angle glaucoma and urinary retention (for example an enlarged prostate) ^{[S10 section 7; S12-S14; U1 p146]}.
• Do not use two products of the same long-acting class together. Labels say a LAMA/LABA or triple product should not be used with other LABA or LAMA products (an overdose may result) ^{[S12 4.1; S13 4.1; S14 7]}.
• Regular four-times-a-day SABA users should stop the regular use when they start a long-acting product and keep the SABA only for symptoms ^{[S12 4.1; S13 4.1; S14 4.1; S10 4.1]}.
• Long-acting products are maintenance medicines. They are NOT for sudden breathlessness; patients must have a SABA with them at all times ^{[S10 4.1; S12 section 1; S13 section 1; S14 4.1; S15 4.1]}.
• The medicine must be used regularly, even when the person feels well ^{[S10 4.1; S12 4.1; S13 4.1; S14 4.1; S15 4.1]}.

Must remember for the exam: reliever SABA for all; maintenance LAMA and/or LABA; ICS only as part of a combination; maintenance inhalers are not for sudden attacks.

Blueprint area: Clinical Care.

5. CTS 2023 stable COPD treatment pathway (the core of the exam)

CTS says its approach is NOT a strict "step" ladder. It is an expanding menu of treatments that matches increasing symptoms and risk ^{[S1 p3]}. SABA as needed goes with every option ^{[S1 Figure 3 note]}.

• "Single inhaler" matters: LAMA/LABA in one inhaler is preferred, and triple should preferably be given in a single inhaler (SITT), not several inhalers, although some patients prefer separate ones ^{[S1 p12, p13, Figure 3 note]}.
• LAMA/LABA is preferred to ICS/LABA because it improves lung function more and has lower pneumonia rates ^{[S1 p7, p9]}.
• Do NOT step down: with moderate to high symptoms and impaired lung function, CTS suggests NOT stepping down from triple to LAMA/LABA, and NOT stepping down from LAMA/LABA to a single long-acting drug (weak). Taking away the ICS can worsen health and lung function, and in high-risk patients it may increase exacerbations, especially with eosinophils of 300 cells/microlitre or more. Step-down may be considered if the step-up did not help or because of significant side effects ^{[S1 p8, p9, p11]}.
• Recommended AGAINST for everyone with stable COPD: ICS monotherapy (strong), maintenance systemic oral steroids such as prednisone, and theophylline ^{[S1 p1, p7, p8, p12]}.
• In low-risk patients on LAMA, LABA or LAMA/LABA, CTS does not suggest adding oral PDE4 inhibitors, mucolytics, statins, anabolic steroids, Chinese herbal medicines or theophylline for symptoms (weak) ^{[S1 p8]}.
• Opioids for severe refractory breathlessness and alpha-1 antitrypsin augmentation for documented severe deficiency are mentioned as "other pharmacotherapies" in CTS Figure 1 (details in the older CTS guideline, not in the library) ^{[S1 p3 Figure 1]}.
• Daily-life example: Mrs. Lee, 68, walks slowly because of breathlessness (mMRC 2, CAT 16, FEV1 62% predicted) and had one moderate flare-up last year. Low risk, symptoms moderate: LAMA/LABA in one inhaler once daily plus a salbutamol puffer as needed. Mr. Singh has the same numbers but had two prednisone/antibiotic courses last year: high risk, so triple therapy in one inhaler.
• What the evidence showed for triple therapy: in the IMPACT trial, moderate or severe exacerbations per year were 0.91 (triple), 1.07 (ICS/LABA) and 1.21 (LAMA/LABA); in ETHOS the exacerbation rate was 24% lower with triple (budesonide 320 mcg) than LAMA/LABA and 13% lower than ICS/LABA; all-cause mortality was lower with triple than with LAMA/LABA (risk ratio 0.58 in ETHOS with budesonide 320 mcg, 0.64 in IMPACT) but not different from ICS/LABA ^{[S1 p12, p13]}. The trial numbers are background; the recommendations above are what to remember.

Must remember for the exam: - Low symptoms and low risk: one long-acting bronchodilator (LAMA or LABA). - Moderate to high symptoms and LOW risk: LAMA/LABA. HIGH risk: triple (LAMA/LABA/ICS), preferably in ONE inhaler. - Never ICS alone. Do not step down triple; ICS/LABA is for COPD with concomitant asthma.

Blueprint area: Clinical Care. Likely exam angle: choosing the right inhaler step for a case.

6. The ICS: benefit, pneumonia and eosinophils

• ICS should only be given as part of combination therapy with long-acting bronchodilators ^{[S1 p8, p12]}.
• Pneumonia is more common with ICS-containing therapy, especially in people with severe and very severe disease. But these are also the people who benefit most. CTS weighed the benefits (fewer flare-ups, better lung function and health, lower mortality in high-risk patients) against the pneumonia risk. For triple therapy versus dual long-acting bronchodilators, the number needed to treat for 1 year to prevent 1 moderate or severe exacerbation is 4, and the number needed to harm to cause 1 pneumonia is 33 ^{[S1 p12]}.
• Pneumonia is a class effect of ICS-containing COPD therapy, with no clear difference between ICS products ^{[S1 p12; S14 section 7]}. In a meta-analysis, deaths from pneumonia were not different with or without ICS ^{[S1 p15]}.
• Labels say to watch for pneumonia, because its signs overlap with a flare-up. Risk factors for pneumonia on an ICS: current smoking, prior pneumonia, low body mass index, severe COPD (fluticasone furoate label) ^{[S14 section 7]}. GOLD adds age 55 or older and eosinophils below 2% ^{[U1 p150]}.
• High ICS doses are not needed: the dose-response curve is flat, with more side effects at higher doses ^{[S1 p12]}.
• Eosinophils of 300 cells/microlitre or more: stronger chance of fewer flare-ups on ICS and more flare-ups if ICS is stopped ^{[S1 p15]}.
• Other ICS effects (labels): oral thrush (rinse the mouth with water and spit it out, do not swallow), adrenal suppression, lower bone density (monitor those with risk factors for osteoporosis), cataract and glaucoma ^{[S14 section 7; S15 section 7]}.
• Thrush daily-life tip: after the inhaler, rinse with plain water and spit, just like after brushing your teeth.

Must remember for the exam: ICS raises pneumonia risk; it is still worth it in high-risk patients. Rinse and spit after every ICS dose. No ICS alone.

Blueprint area: Clinical Care.

7. Inhaler devices and technique

• Inhaler technique is one of the most important parts of COPD care. Errors are linked to more ED visits, hospital stays, steroid and antibiotic use ^{[S1 p15]}.
• Using several devices that need the SAME breathing technique is linked to fewer flare-ups than using devices that need different techniques ^{[S1 p15]}.
• Triple therapy in one inhaler improved health status and lung function more than multiple inhalers (INTREPID) ^{[S1 p15]}. All guidelines advise minimizing the number of inhalers and the number of different types ^{[S1 p16]}.
• Device choice is a shared decision: technique, preference, cost/insurance, clinical course and also the environment ^{[S1 p15]}.
• Choosing Wisely Canada item 8: do not prescribe a greenhouse-gas-heavy pMDI when an equal alternative (a DPI, a soft-mist inhaler, or a low-greenhouse-gas pMDI) is available and the patient uses it well and agrees. Not suitable for everyone: preschool children, certain cognitive limits, end-stage lung disease, muscle weakness and respiratory emergencies ^{[S2 item 8]}. SABA inhalers are about 71% of all inhaler use in Canada ^{[S1 p15]}.
• Internationally (GOLD): pMDIs and soft-mist inhalers need a slow, deep breath in; DPIs need a forceful breath in. If a person cannot breathe in forcefully (weak, very breathless), switch to a pMDI (with a spacer/VHC) or a soft-mist inhaler. On average, more than two-thirds of people make at least one error. Use "teach-back" (ask the patient to show you). Pharmacists can improve technique and adherence. Do not switch devices for cost without retraining ^{[U1 p70-72]}.
• A VHC/spacer helps with pMDI coordination and reduces mouth deposition of ICS (less thrush) ^{[U1 p71; S16 section 7]}.
• GOLD: pharmacist-, physician-, physiotherapist- and nurse-led teaching can improve inhaler technique and adherence; package leaflets alone are not enough; if a person already uses their device correctly, new therapy is best prescribed in the same device ^{[U1 p71]}.
• CTS says single-inhaler triple therapy is favoured because of potential extra benefit, better adherence and fewer technique errors ^{[S1 p13]}.

• Milk protein warning: Trelegy, Anoro and Ultibro are contraindicated in people with severe hypersensitivity to milk proteins (the powder carrier lactose contains milk protein); Spiriva HandiHaler capsules also contain lactose carrying milk protein ^{[S12 section 2; S13 section 2; S14 section 2; S10 section 6]}.
• Daily-life example: Mr. Chen, 82, has weak hands and takes a DPI that needs a strong, fast breath. His breath is too weak, so the dose does not reach the lungs. The pharmacist asks him to demonstrate, then suggests a device with a spacer or a soft-mist inhaler.

Must remember for the exam: check technique at every visit; DPI = strong fast breath, pMDI/soft-mist = slow deep breath; never swallow capsules; shake and prime pMDIs; rinse and spit after an ICS; fewer and same-type devices are better; triple in one inhaler is preferred.

Blueprint area: Clinical Care; Distribution.

8. SABA and SAMA (relievers)

• SABA as needed is for everybody with COPD at every severity ^{[S1 p13, Figure 3 note]}.
• Needing the reliever more than usual, or relief that does not last or is less effective, is a sign of worsening disease and needs a prompt re-evaluation ^{[S11 Not for acute use; S14 section 7; S16 4.1]}.
• Long-acting maintenance products are not a replacement for the reliever ^{[S10 4.1; S12 4.1; S13 4.1; S14 4.1]}.
• GOLD: a SABA plus a SAMA (for example salbutamol plus ipratropium) is better than either alone for FEV1 and symptoms; ipratropium side effects are mainly dry mouth and sometimes a bitter, metallic taste ^{[U1 p144-147]}. The Canadian ipratropium label was not opened (unconfirmed).
• Using SAMA together with a LAMA is not advised (duplicate muscarinic blockers); labels say not to use more than one muscarinic antagonist product ^{[S11 Excessive use; S14 section 7]}.
• Beta-blockers weaken beta2-agonists. Non-cardioselective ones (for example propranolol) should usually not be given with salbutamol; labels advise cardioselective ones only with caution and when needed ^{[S16 Table 3; S14 section 9]}.

Must remember for the exam: keep a SABA with the patient always; do not double up long-acting drugs of the same class; avoid non-selective beta-blockers.

Blueprint area: Clinical Care.

9. Exacerbations: what to do (acute flare-up)

^[S1] does not cover acute exacerbations. This section is mainly from GOLD 2026 ^[U1] (international), with Canadian points where found. Canadian labels say long-acting products are not for relief of an acute attack and should not be started in acutely deteriorating COPD ^{[S11 Not for acute use; S14 section 7; S12 section 1; S13 section 1; S15 section 1]}.

• Most flare-ups (over 80%) are treated at home with bronchodilators, steroids and antibiotics ^{[U1 p101]}. Admission is considered depending on the severity and the underlying disease ^{[U1 p101]}.
• Bronchodilators first: inhaled SABA, with or without a short-acting anticholinergic (SAMA), is the initial treatment. A pMDI (with or without spacer) works as well as a nebulizer. If a nebulizer is used, air-driven is preferred over oxygen-driven (oxygen-driven can raise the carbon dioxide level). Avoid high SABA doses. Continue the long-acting inhalers, or start them before discharge ^{[U1 p103]}.
• Intravenous theophylline or aminophylline are not recommended because of significant side effects ^{[U1 p103]}.
• Systemic corticosteroids: prednisone 40 mg (prednisone-equivalent) per day for 5 days is recommended. Steroids shorten recovery and improve lung function, oxygenation, relapse and length of hospital stay. Oral works as well as IV. Even short bursts raise the later risk of pneumonia, sepsis and death, so use them for significant flare-ups only ^{[U1 p103]}.
• Canada/ACCP-CTS 2015: systemic corticosteroids for an acute flare-up are suggested to reduce hospital-needing flare-ups in the next 30 days; do not give systemic steroids long-term to prevent flare-ups after those 30 days ^{[S17 rec 27, 28]}.
• Antibiotics (GOLD): give when the patient has at least two of these four signs - more breathlessness, fever, more sputum volume, more sputum purulence - and increased purulence is one of them; or when mechanical ventilation (invasive or non-invasive) is needed; or when a sputum culture during an earlier flare-up was positive. Increased sputum purulence is the key sign pointing to a bacterial infection ^{[U1 p104]}.
• Antibiotic choice follows local resistance. Usual first choices: an aminopenicillin with clavulanic acid, a macrolide, or a tetracycline; a quinolone only in selected patients. Duration: 5 to 7 days is the usual recommendation; GOLD recommends 5 days or less for outpatients ^{[U1 p104-105]}.
• NOTE: Choosing Wisely Canada item 4 says do not treat an ordinary adult cough with antibiotics unless bacterial pneumonia is suspected ^{[S2 item 4]}. That item is about acute cough, not a COPD flare-up with purulent sputum.
• Other (GOLD): treat the hospital patient's other conditions; blood clot prevention is recommended in hospitalized patients; enforce smoking cessation ^{[U1 p105]}.
• Oxygen in a flare-up: if low in oxygen, start controlled oxygen therapy; consider NIV if breathing effort or gas exchange is a problem ^{[U1 p101]}. The exact oxygen saturation target was not found in the files read (unconfirmed).
• After a flare-up: review medicines and technique, start or restart maintenance therapy, offer pulmonary rehabilitation within 4 weeks of discharge ^{[U1 p109; S17 rec 4]}. Poor medication reconciliation at discharge contributes to readmissions (up to 22% within 30 days in some countries) ^{[S1 p2]}. GOLD 2026 says readmissions occur in 30% to 50% of patients within 30 days of discharge after a hospital stay for a flare-up ^{[U1 p108]}.

Must remember for the exam: SABA (+/- SAMA) first; prednisone 40 mg for 5 days; antibiotics when sputum is purulent with increased breathlessness or volume, or ventilation is needed; no IV theophylline; review technique and plan rehabilitation after a flare-up.

Blueprint area: Clinical Care.

10. Oxygen

• LTOT (long-term oxygen therapy) is for stable COPD with severe low oxygen: PaO2 55 mmHg or below, or oxygen saturation (SaO2) 88% or below, confirmed twice over three weeks (with or without a high carbon dioxide level); or PaO2 between 55 and 60 mmHg (or SaO2 88%) with pulmonary hypertension, ankle swelling suggesting heart failure, or polycythemia (hematocrit above 55%) ^{[U1 p76]}.
• LTOT has been shown to prolong survival in severe resting low oxygen. GOLD says to use it more than 15 hours a day, but a newer trial showed that 24 hours a day gave no lower risk of hospital stay or death than 15 hours, so the more-than-15-hours advice is not supported by that newer trial ^{[U1 p76]}.
• Canadian home-oxygen guidance was not found in the library (unconfirmed). Smoking while using oxygen is a fire danger; this safety point was not in the files read (unconfirmed).
• RSV vaccine is specifically recommended for adults on home oxygen or chronic oxygen therapy ^{[S5 High risk individuals]}.

Must remember for the exam: LTOT is for stable COPD with PaO2 55 mmHg or below (or 55 to 60 mmHg with heart or blood complications), used for most of the day.

Blueprint area: Clinical Care.

11. Vaccines (Canadian Immunization Guide)

• Influenza: pulmonary disorders are on the list of conditions for which the yearly flu shot is particularly important; adults 65 and older also high-risk. Adults 65 and over should preferably get a high-dose, adjuvanted or recombinant vaccine (IIV-HD, IIV-Adj or RIV). The nasal live vaccine (LAIV) is NOT recommended for adults with chronic health conditions (use the injectable) ^{[S4 List 1, adults 65 and older, adults 18 to 59]}.
• Pneumococcal: chronic lung disease (particularly COPD and emphysema) is on the list of conditions that raise the risk of invasive pneumococcal disease. Adults 65 and older, and adults under 65 with a risk factor, should receive 1 dose of Pneu-C-20 or Pneu-C-21 (a conjugate vaccine), regardless of earlier pneumococcal vaccines. In previously immunized adults 65 and older, give it at least 1 year after the last earlier pneumococcal dose (Pneu-C-13, Pneu-C-15 or Pneu-P-23). Smoking itself is also a risk factor (especially over 50). Pneu-P-23 (Pneumovax 23) was discontinued in Canada in August 2025 ^{[S3 Table 1, key points, adult recommendations]}.
• RSV: COPD is listed among the conditions for which RSV vaccination is particularly important. One dose is recommended for all adults 75 and older, for adults 65 to 74 at increased risk (including COPD), and for adults 18 and older on home oxygen or chronic oxygen therapy, among others. Best timed just before the RSV season. Adults 18 to 64 at increased risk may consider one dose after discussion with a provider ^{[S5 List 2, recommendations for adults]}.
• COVID-19: recommended for all adults 65 and older and for people with underlying medical conditions that raise the risk of severe COVID-19 ^{[S6 recommendations for use]}.
• Pertussis (Tdap): one dose of Tdap for adults who have not received a pertussis-containing vaccine in adulthood ^{[S7 routine immunization of adults]}.
• Shingles: recombinant zoster vaccine (RZV) for adults 50 and older without contraindications ^[S8].
• GOLD agrees that people with COPD should have flu, pneumococcal, RSV, COVID-19, Tdap and shingles vaccines ^{[U1 p57]}.
• WARNING: the older ACCP/CTS 2015 guideline refers to the 23-valent pneumococcal vaccine ^{[S17 rec 1]}. Current Canadian advice is Pneu-C-20 or Pneu-C-21 (above).
• Daily-life example: Mr. Brown, 70, has COPD and never had a pneumococcal shot. One dose of Pneu-C-20 or Pneu-C-21 covers him; he also gets an annual flu shot and, before the RSV season, one RSV dose.

Must remember for the exam: yearly flu shot (injectable, high-dose/adjuvanted/recombinant if 65+); 1 dose Pneu-C-20 or Pneu-C-21; RSV, COVID-19, Tdap and shingles as per Canadian schedules.

Blueprint area: Clinical Care.

12. Oral add-on medicines for repeat exacerbations

For patients at HIGH risk who still flare up despite triple therapy (CTS 2023 ^{[S1 p9, p12]}):

• Macrolide maintenance (azithromycin) is RECOMMENDED (strong). The benefits (studied over one year) must be weighed against bacterial resistance, hearing loss and heart rhythm problems (QT prolongation and drug interactions). Use in appropriate patients: normal QT on an ECG, no significant drug interactions, and no evidence of infection with atypical mycobacteria (nontuberculous) ^{[S1 p9, p12]}.
• International extra (GOLD): azithromycin 250 mg daily or 500 mg three times a week (or erythromycin 250 mg twice a day) for one year reduced flare-ups; bacterial resistance, QT prolongation and hearing problems occurred; less benefit in active smokers; no data beyond 1 year ^{[U1 p152]}. GOLD suggests azithromycin for people who are not currently smoking ^{[U1 p66]}.
• Roflumilast (a PDE4 inhibitor, taken by mouth once daily, not a bronchodilator) or N-acetylcysteine (NAC): SUGGESTED (weak) for patients with a chronic bronchitis type of COPD, high risk and ongoing flare-ups on triple ^{[S1 p9, p12]}.
• Roflumilast side effects (GOLD): diarrhea, nausea, reduced appetite, weight loss (about 2 kg on average), abdominal pain, sleep problems, headache; monitor weight, avoid in underweight patients, caution with depression ^{[U1 p151]}. The Health Canada roflumilast label was not found (unconfirmed), so the dose is not given here.
• GOLD: roflumilast is for FEV1 below 50%, chronic bronchitis symptoms and a history of a flare-up needing hospital ^{[U1 p66]}. The NAC dose was not given by CTS; GOLD describes that 600 mg twice daily did not significantly reduce exacerbations in mild to moderate COPD ^{[U1 p152]} (unconfirmed for Canadian practice).
• Recommended AGAINST (CTS): theophylline (modest FEV1 gain but adverse events and many drug interactions), maintenance oral prednisone, and ICS alone ^{[S1 p1, p8]}. GOLD: theophylline interacts with erythromycin, ciprofloxacin, allopurinol, cimetidine and fluvoxamine ^{[U1 p147]}.
• Beyond Canada: GOLD also lists dupilumab and mepolizumab for people with high eosinophils (300 cells/microlitre or more) who keep flaring on triple therapy ^{[U1 p66]}. Canadian label status for COPD was not checked (see section 18).
• Daily-life example: Mr. Kim is on a single-inhaler triple product and still needed antibiotics and prednisone three times this year. His doctor checks his ECG and drug list; if the QT is normal and no interacting drugs, azithromycin may be added. The pharmacist watches for other QT-prolonging drugs.

Must remember for the exam: after triple therapy still fails in a high-risk patient, add azithromycin (strong) or, for chronic bronchitis, roflumilast or NAC (weak). Check ECG (QT), interactions and hearing. Do not use theophylline, long-term prednisone or ICS alone.

Blueprint area: Clinical Care.

13. Alpha-1 antitrypsin (A1AT) deficiency

• GOLD: test all people diagnosed with COPD; a concentration below 20% of normal suggests homozygous deficiency; test and refer family members too ^{[U1 p48]}.
• GOLD: augmentation (replacement) therapy has mostly been studied in ZZ genotype; never- or ex-smokers with FEV1 35 to 60% predicted have been suggested as most suitable. Heterozygotes (Z/M) do not usually need it; stopping smoking is the key ^{[U1 p155]}.
• CTS 2023 only lists A1AT augmentation as an option for documented severe deficiency ^{[S1 p3 Figure 1]}.
• UNVERIFIED / needs Numan's copy: the 2025 CTS guideline on A1AT testing and augmentation is only on the publisher site (Taylor & Francis) and was not saved. Do not use it for exam facts until the copy is added.

Blueprint area: Clinical Care.

14. Comorbidities and other medicines

• Heart disease and COPD overlap a lot. Flare-ups raise the risk of heart attack and stroke ^{[S1 p13]}. Beta-agonists and antimuscarinics can cause arrhythmias (atrial fibrillation, tachycardia); labels advise caution in unstable cardiovascular disease, QT prolongation, low potassium or QT-prolonging drugs ^{[S10; S12-S14]}.
• GOLD: in atrial fibrillation there is no contraindication to any rate or rhythm control drug in COPD, including beta-blockers; caution with SABA and theophylline; the AF does not change the COPD treatment ^{[U1 p117]}. GOLD also says there is no evidence that beta-blockers should be used in COPD without a heart reason (metoprolol did not lower flare-ups and more people had admissions) ^{[U1 p153]}.
• Pulmonary rehabilitation may help anxiety symptoms. GOLD found no evidence of benefit from benzodiazepines for breathlessness; opioids for severe refractory breathlessness are mentioned by CTS and GOLD ^{[U1 p83; S1 Figure 1]}.
• Osteoporosis and ICS: bone density can fall on long-term ICS; consider monitoring bone health ^{[S14; S15]}.
• Lung cancer: smoking history makes screening relevant; see Choosing Wisely Canada item 2 ^[S2].
• Hypokalemia: SABA/LABA with diuretics, steroids or xanthines can lower potassium ^{[S14 section 9; S16 section 9]}.
• Other drug interactions of long-acting inhalers (Trelegy label): strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin and others) raise fluticasone furoate and vilanterol exposure: avoid unless benefit outweighs risk and monitor for systemic steroid effects and heart effects; MAOIs and tricyclic antidepressants and other QT-prolonging drugs may add cardiovascular and QT effects; other sympathomimetic drugs add side effects; beta-blockers (including eye drops) can weaken the effect and cause severe bronchospasm ^{[S14 section 9, Table 6]}.

Blueprint area: Clinical Care.

15. Counselling and adherence (what to tell the patient)

1. Maintenance inhalers (LAMA, LABA, ICS, triple) are taken EVERY day, even when well. They do not work as a rescue ^[S10-S15].
2. Always carry the rescue puffer (SABA). If the usual dose gives less relief or lasts under 3 hours, or you need it more than usual, call the clinic ^{[S16 4.1; S14 7]}.
3. Show your technique at every visit. Never swallow capsules; breathe in through the device ^{[S10 4.4; S13 4.4]}.
4. After any ICS-containing inhaler, rinse your mouth with plain water and spit it out ^{[S14 4.4; S15]}.
5. Stop smoking; ask about help (counselling, NRT, bupropion, varenicline) ^{[S9; S14 4.1]}.
6. Yearly flu shot, pneumococcal, RSV, COVID-19, Tdap and shingles vaccines as recommended ^[S3-S8].
7. Do not use two long-acting products at the same time unless prescribed; do not double up on LAMA, LABA ^{[S14 7]}.
8. Eye safety: with LAMA, do not let the mist or powder get in your eyes; eye pain, blurred vision, halos and red eyes need urgent medical help (narrow-angle glaucoma) ^{[S11; S10 7]}.
9. Difficulty passing urine on a LAMA needs a call ^{[S11; S10]}.
10. Pneumonia warning with ICS: fever, more sputum or worse breathlessness need a check, because it can look like a flare-up ^{[S14 7]}.
11. Join pulmonary rehabilitation; keep active; keep a written action plan ^{[S1 p7; S17]}.
12. Pharmacist checks: reliever refills far above maintenance refills, no maintenance inhaler at all, two inhalers of the same long-acting class, technique, device mix (use the same type if possible), drug interactions, vaccines, and when to refer. - Adherence: poor discharge medication reconciliation causes readmissions; ask about missed doses without blame (cost, forgetting, fear of steroids, trouble with the device) and fix the cause ^{[S1 p2, p15]}.

Blueprint area: Clinical Care; Communication and Collaboration.

16. When to refer or escalate

• Send for spirometry if COPD is suspected but not confirmed; do not start long-term maintenance inhalers without it (Choosing Wisely Canada) ^{[S2 item 1]}.
• Refer or call the prescriber when: flare-ups needing antibiotics and/or prednisone keep happening (2 or more in a year = high risk) or there is any hospital or ED visit ^{[S1 p9]}; breathlessness is getting worse or the reliever is needed more or works less ^{[S11; S14 section 7; S16 4.1]}; pneumonia is suspected on an ICS (its signs overlap with a flare-up) ^{[S14 section 7]}; signs of acute narrow-angle glaucoma (eye pain or discomfort, blurred vision, halos, red eyes) or difficulty passing urine on a LAMA ^{[S10 section 7; S11]}.
• A young patient with COPD, or one with a family history, should be considered for alpha-1 antitrypsin testing (GOLD: all people with COPD should be tested) ^{[U1 p48]}.
• Weight loss on roflumilast, and QT or hearing problems on azithromycin, need review ^{[U1 p151-152; S1 p12]}.
• The Canadian hospital-admission criteria and a formal Canadian referral list for COPD are not in the CTS 2023 guideline or the library (unconfirmed). A flare-up needing hospital or the ED is by definition severe ^{[S1 p9]}.

Blueprint area: Clinical Care; Communication and Collaboration.

17. Quick quiz (study yourself)

1. What test confirms COPD?
2. What value of the post-bronchodilator FEV1/FVC confirms it?
3. How is HIGH risk of exacerbations defined?
4. A patient with mMRC 2, CAT 14, FEV1 60% and one moderate flare-up last year: what is the CTS first choice?
5. A patient with the same scores but two moderate flare-ups: what?
6. Which drug is never used alone in COPD?
7. What is the number needed to harm for pneumonia with triple therapy (1 year)?
8. What should a patient do after using an ICS inhaler?
9. What is the first step for a COPD patient who smokes?
10. Which pneumococcal vaccines are advised in Canada for adults 65 and older?

Answers: 1. Post-bronchodilator spirometry. 2. Below 0.70. 3. 2 or more moderate flare-ups, or 1 or more severe (hospital or ED), in the past year. 4. LAMA/LABA in one inhaler (plus SABA as needed). 5. Triple LAMA/LABA/ICS, preferably in one inhaler. 6. ICS (monotherapy). 7. 33 (and the number needed to treat is 4 for one fewer moderate or severe flare-up). 8. Rinse the mouth with water and spit. 9. Smoking cessation counselling (with medicine options). 10. One dose of Pneu-C-20 or Pneu-C-21.

18. Label vs guideline, and Canada vs international (label wording and GOLD-only differences are not tested in the MCQs; where a question touches one of these topics, its stem names CTS 2023 or the Canadian guide and the Canadian answer is the key)

Unconfirmed items

• Not in the CTS 2023 guideline and not found in a Canadian source in the library: acute exacerbation treatment (steroid dose, antibiotic rules and duration come from GOLD 2026), oxygen targets, home oxygen rules, pulmonary rehabilitation details (CTS 2010 not saved), and smoking-cessation drug doses.
• The CTS 2025 alpha-1 antitrypsin testing and augmentation guideline is on the publisher site only (Taylor & Francis). NOT saved; needs Numan's copy.
• Health Canada labels were not opened for ipratropium (Atrovent), roflumilast (Daliresp), azithromycin, and the other LAMA, LABA and LAMA/LABA products (Onbrez, Striverdi, Seebri, Incruse, Tudorza, Inspiolto, Duaklir): the Health Canada drug database returned 503 errors and a web search found no roflumilast monograph. Roflumilast and NAC doses are therefore not given.
• Spiriva Respimat (2019) and Spiriva HandiHaler (2022) labels are older than the guideline; newer revisions may exist.
• CTS Figures 1 and 3 were pictures. Their content was taken from the text, tables and footnotes of the guideline.
• The CAT and mMRC score meanings come from CTS thresholds and the GOLD scale description; the full item wording was not read.
• Canadian referral rules, the exact oxygen saturation target in a flare-up, fire safety with home oxygen and the Canadian status of biologics for COPD were not confirmed.
• Doses are for exam study only, not for real patients. Not affiliated with or endorsed by PEBC.

Study aid, not medical advice. Check official sources before any patient decision.

MapleRxPrep

Found an error? Email [email protected] with the file name, version and page.